FDA Drug Safety Communication: Safety Review Update of Recombinant Human Growth Hormone (Somatropin) and Possible Increased Risk of Death

Why It Matters

The clarification sustains clinical confidence and market stability while signaling that further safety data could influence prescribing practices and regulatory actions.

Key Takeaways

• FDA finds evidence on death risk inconclusive.
• SAGhE study design flaws limit reliability.
• No adverse signal from AERS or literature.
• Physicians advised to follow label guidelines.
• Further data expected Spring 2012.

Pulse Analysis

The recombinant human growth hormone known as somatropin has been a mainstay therapy for children with growth disorders and for adult GH deficiency. Since its approval, the product has generated billions in annual sales, making it a critical revenue stream for biotech firms and specialty pharmacies. Concerns about long‑term safety resurfaced in 2010 when the French SAGhE cohort suggested a possible increase in mortality among treated patients. That signal prompted the FDA to issue a Drug Safety Communication, sparking intense scrutiny from clinicians, insurers, and investors alike.

In its latest safety review, the FDA highlighted several methodological weaknesses in the SAGhE analysis, including incomplete follow‑up, potential selection bias, and limited control for confounding comorbidities. The agency also examined a broader evidence base—U.S. cohort studies, UK cancer risk assessments, and the FDA’s own Adverse Event Reporting System—and found no corroborating trend toward higher death rates. Consequently, the regulator concluded that the current data are insufficient to establish a causal link between somatropin and increased mortality, and it reaffirmed existing prescribing recommendations.

The FDA’s inconclusive stance carries practical implications for the market. Manufacturers can continue to promote somatropin without immediate label changes, preserving revenue and supply chain stability. However, the promise of additional SAGhE data in spring 2012 means that payers and providers must stay alert to any new findings that could reshape risk‑benefit calculations. For clinicians, the guidance reinforces the importance of adhering to approved indications and monitoring patients per standard protocols, while researchers are encouraged to design more rigorous long‑term safety studies to close the evidentiary gap.